Connecticut is currently home to 1248 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including New Haven, Hartford, Farmington and Stamford. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
A Study of ATG-031 in Advanced Solid Tumors or B-cell Non-Hodgkin Lymphomas
NCT06028373
Recruiting
ATG-031 study (alias: PERFORM) is a multicenter, open-label, Phase 1 study of ATG-031 in patients with advanced solid tumors or B-NHL. The study design includes a Dose Escalation Phase and a Dose Expansion Phase, and will enroll patients with advanced solid tumors (i.e., preferred tumor types) or relapsed/refractory (R/R) B-NHLs. The study's primary objective is to evaluate the safety and tolerability of ATG-031 and determine the RP2D（Refered Phase II dose） of ATG-031.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/05/2025
Locations: Yale University, New Haven, Connecticut
Conditions: Advanced Solid Tumors, B-cell Non-Hodgkin Lymphomas
Register for Updates
Catheter-Related Early Thromboprophylaxis With Enoxaparin Studies
NCT04924322
Recruiting
The goal of the CRETE Studies is to investigate the newly identified age-dependent heterogeneity in the efficacy of enoxaparin in reducing the risk of central venous catheter-associated deep venous thrombosis in critically ill children.
Gender:
ALL
Ages:
17 years and below
Trial Updated:
06/05/2025
Locations: Yale-New Haven Children's Hospital, New Haven, Connecticut
Conditions: Deep Venous Thrombosis
Register for Updates
Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer
NCT04221542
Recruiting
Evaluate the safety and tolerability of AMG 509 in adult participants and determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D). Part 2 is now closed to accrual.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
06/05/2025
Locations: Yale New Haven Hospital, New Haven, Connecticut
Conditions: Prostate Cancer
Register for Updates
HCRN Endoscopic Versus Shunt Treatment of Hydrocephalus in Infants
NCT04177914
Recruiting
Hydrocephalus is a potentially debilitating neurological condition that primarily affects babies under a year of age and has traditionally been treated by inserting a shunt between the brain and the abdomen. A newer endoscopic procedure offers hope of shunt- free treatment that may reduce complications over a child's life, but it is not clear if the endoscopic procedure results in similar intellectual outcome as shunt. Therefore, the investigators propose a randomized trial to compare intellectu... Read More
Gender:
ALL
Ages:
Between 1 day and 104 weeks
Trial Updated:
06/05/2025
Locations: Yale University, New Haven, Connecticut
Conditions: Hydrocephalus
Register for Updates
Gender Related Differences in the Acute Effects of Delta-9-Tetrahydrocannabinol in Healthy Humans: Sub-Study I
NCT02811510
Recruiting
The purpose of the study is to characterize the acute effects of cannabinoids in women relative to men and to begin probing the mechanisms that may underlie gender differences.
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
06/05/2025
Locations: Biological Studies Unit at the VA Connecticut Healthcare System, Yale School of Medicine, West Haven, Connecticut
Conditions: Cannabis
Register for Updates
Gender Related Differences in the Acute Effects of Delta-9-Tetrahydrocannabinol in Healthy Humans
NCT02781519
Recruiting
The purpose of the study is to characterize the acute effects of cannabinoids in women relative to men and to begin probing the mechanisms that may underlie gender differences.
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
06/05/2025
Locations: Biological Studies Unit at the VA Connecticut Healthcare System, Yale School of Medicine, West Haven, Connecticut
Conditions: Cannabis
Register for Updates
The Cancer of the Pancreas Screening-5 CAPS5)Study
NCT02000089
Recruiting
Johns Hopkins clinical research office quality assurance group will monitor and audit this study at Johns Hopkins. The Sub Investigator at each site will be responsible for internal monitoring at their site.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/05/2025
Locations: Yale University, New Haven, Connecticut
Conditions: Pancreas Cancer, Peutz-Jeghers Syndrome (PJS), Gene Mutation, Germline Mutation Carrier, Lynch Syndrome
Register for Updates
A Novel Program Using Ride-on Toys to Improve Upper Extremity Function in Children With Hemiplegia
NCT06579027
Recruiting
The purpose of this study is to assess the feasibility and utility of 2 types of play-based training programs co-delivered by researchers and caregivers within home/community settings to promote arm function among 3-to-8-year-old children with hemiplegia. Specifically, investigators will assess the feasibility of implementation and acceptance/satisfaction associated with a researcher-caregiver co-delivered community-based training program involving either joystick-operated powered ride-on toys (... Read More
Gender:
ALL
Ages:
Between 3 years and 8 years
Trial Updated:
06/04/2025
Locations: Physical Therapy Program, Department of Kinesiology, University of Connecticut, Storrs, Connecticut
Conditions: Hemiplegia, Cerebral Palsy, Children, Only
Register for Updates
Tka Assay for CDK4/6i
NCT06572800
Recruiting
This clinical trial assesses whether using a test developed by DiviTum can identify optimal levels of CDK 4/6 inhibitor medications in the blood and whether assessing medical compliance and drug-drug interactions can optimize (improve) these levels in patients with estrogen receptor (ER) or progesterone receptor (PR) positive, and human epidermal growth factor receptor 2 (HER2)-negative breast cancer that has spread from where it first started (primary site) to other places in the body (metastat... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
06/04/2025
Locations: Smilow Cancer Hospital-Derby Care Center, Derby, Connecticut
Conditions: Anatomic Stage IV Breast Cancer AJCC v8, Metastatic HER2-Negative Breast Carcinoma
Register for Updates
Mindfulness-based Neurofeedback to Augment Psychotherapy for Adults With Borderline Personality Disorder
NCT06446765
Recruiting
The purpose of this study is to test the ability of mindfulness-based real time functional magnetic resonance imaging (fMRI) neurofeedback (mbNF) to increase the benefits of evidence-based psychotherapy for adults with Borderline Personality Disorder (BPD).
Gender:
ALL
Ages:
Between 18 years and 60 years
Trial Updated:
06/04/2025
Locations: Connecticut Mental Health Center, New Haven, Connecticut
Conditions: Borderline Personality Disorder
Register for Updates
The Impact of Blood Flow Restriction Training in Adolescents After ACL Reconstruction: A Randomized Controlled Trial
NCT05754632
Recruiting
While there are a number studies that have reported on the use of blood flow restriction training (BFRT) in the adult population, there is limited information about the use of BFRT in the adolescent population. This study aims to evaluate the use of BFRT in conjunction with traditional anterior ligament reconstruction (ACLR) rehabilitation in adolescents. The purpose of this study is to compare the addition of a BFRT based exercise protocol to a standard ACL rehabilitation protocol in adolescen... Read More
Gender:
ALL
Ages:
Between 12 years and 18 years
Trial Updated:
06/04/2025
Locations: Connecticut Children's Sports Physical Therapy, Farmington, Connecticut
Conditions: Anterior Cruciate Ligament Injuries, Knee Injuries, Quadriceps Muscle Atrophy
Register for Updates
XTX301 in Patients With Advanced Solid Tumors
NCT05684965
Recruiting
This is a first-in-human, multicenter, Phase 1/2, open-label study designed to evaluate the safety and tolerability of XTX301 as monotherapy in patients with advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/04/2025
Locations: Yale Cancer Center, New Haven, Connecticut
Conditions: Advanced Solid Tumor
Register for Updates